Please assess the completion status of the following clinical trial:

Trial Title: Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Patients 18 years of age and older presenting to the Stanford Preoperative Evaluation Clinic prior to elective orthopedic surgical procedures or elective vascular surgical procedures not involving the abdominal aorta or carotid arteries.~Exclusion Criteria:~Patients will be excluded from participation if they have one or more of the following conditions:~1. Evidence of active local or systemic infection as demonstrated by fever, leukocytosis (white blood cell count \> 11,000/ul), productive cough, new infiltrate on chest x-ray, or purulent drainage from any source~2. End-stage renal disease~3. A history of diabetic neuropathy~4. A malignancy other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the previous 5 years~5. Leukopenia (white blood cell count \< 2,000/ul)~6. Thrombocytopenia (platelet count \< 100,000/ul)~7. Abnormal liver function test result (aspartate aminotransferase or alanine aminotransferase level ≥1.5-fold the upper limit of normal)~8. A history or infection with tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus~9. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: ACTIVE_COMPARATOR): Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
- Saline injection (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).